Mohsen Jafari

Mohsen Jafari

Auto-generated profile, based on publicly available information

Mohsen Jafari

Abu-Ali Sina Organ Transplant Hospital, Research Committee, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Renal Endocrinology
Verified
Journal Article
Open access
PDF file
AKAli Rastegar Kashkouli
Ali Rastegar Kashkouli
MJMohsen Jafari
Mohsen Jafari
PYPourya Yousefi
Pourya Yousefi
Vaccination is one of the most important public health strategies to reduce mortality and morbidity of various infectious diseases. The COVID-19 pandemic was declared, on March 11, 2020, since then, the virus has spread rapidly, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have played the main substantial role in advancing the management of the COVID-19 pandemic. As is well known, sex/gender-related differences affect vaccine efficacy, response, and acceptability. This review aims to compare the effects of sexual dimorphism and gender-related differences factors on the efficacy, responses, and acceptance of the COVID-19 vaccines. As far as the COVID-19 vaccine effectiveness is concerned, both males and females with the COVID-19 vaccine showed consistent and impressive efficacy; although males showed slightly greater efficacy, there was no significant correlation between the efficacy of the COVID-19 vaccine and their sex or gender differences. Consequently, to reduce adverse reactions in females, sex differences should be considered in the design of the COVID-19 vaccine. It is also essential to conduct pragmatic trials to verify whether sex differences in vaccine response and efficacy vary with age.

1 April 2023 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
MJMohsen Jafari
Mohsen Jafari
ARAli Rastegar-Kashkouli
Ali Rastegar-Kashkouli
PYPourya Yousefi
Pourya Yousefi
AKAshkan Khavaran
Ashkan Khavaran
MSMohammad Sharifi
Mohammad Sharifi
DRDordaneh Rastegar
Dordaneh Rastegar
Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by elevated or inappropriately parathormone levels. The most common cause of PHPT is solitary parathyroid adenoma (80-85%). Parathyroid surgery generally encompasses symptomatic PHPT and asymptomatic patients who meet the surgical guideline criteria. If surgery is contraindicated, several non-surgical ablative techniques can be conducted to eliminate the pathological parathyroid tissue, which causes tissue necrosis in the affected gland. This review aims to look into the most recent studies on the efficacy of percutaneous ethanol injection therapy (PEIT), laser ablation (LA), radiofrequency ablation (RFA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU) in treatment of PHPT and analyze their application prospects. PEIT is a classic method that is less commonly used nowadays. The analysis of thermal ablation methods revealed that LA is inefficient and requires considerable repetition. Meanwhile, the MWA and RFA have a cure rate of over 85% and fewer complications; it seems that they have the potential to replace surgical methods in the future.

29 January 2024 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
ARAli Rastegar-Kashkouli
Ali Rastegar-Kashkouli
PYPourya Yousefi
Pourya Yousefi
MJMohsen Jafari
Mohsen Jafari
ATAmir Mohammad Taravati
Amir Mohammad Taravati
SSSeyedeh Ghazal Shahrokh
Seyedeh Ghazal Shahrokh
DRDordaneh Rastegar
Dordaneh Rastegar
Sickle cell nephropathy (SCN) poses an important challenge in the realm of sickle cell disease (SCD) and sickle cell trait (SCT), especially impacting the pediatric population and progressing to chronic kidney disease (CKD) in adulthood. This review navigates through the epidemiology of SCN, emphasizing its variable clinical course and the age-related dynamics of onset. The intricate challenges in diagnosis are explored, highlighting the evolving landscape of early detection and treatment strategies. The prevalence of SCN is intricately linked to the global distribution of SCD and SCT, with higher incidences in regions where these conditions prevail. Diagnosing SCN presents significant challenges due to its variable clinical course, necessitating advanced imaging techniques and novel biomarkers. Promising biomarkers such as KIM-1 and MCP-1 show potential for early detection and intervention, addressing the limitations of conventional diagnostic methods. Precision medicine, focusing on genetic profiling, emerges as a crucial approach for risk stratification and personalized treatment plans. The multifaceted clinical manifestations of SCN, including hematuria, proteinuria, and hypertension, underscore the importance of timely intervention. Treatment strategies involve the administration of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, hydroxyurea for preventing chronic organ damage, and kidney transplantation for end-stage renal disease. Early diagnosis and intervention are critical to mitigate the progression of SCN and its associated complications, emphasizing the need for collaborative efforts in research and precision medicine to improve outcomes for individuals with SCN.

3 June 2023 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
ARAli Rastegar-Kashkouli
Ali Rastegar-Kashkouli
MJMohsen Jafari
Mohsen Jafari
SKSaina Karami
Saina Karami
PYPourya Yousefi
Pourya Yousefi
ATAmir Mohammad Taravati
Amir Mohammad Taravati
MKMohammad Ebrahimi Kalan
Mohammad Ebrahimi Kalan
Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.

1 January 2024 in Journal of Renal Endocrinology
Verified
Journal Article
Open access
PDF file
MJMohsen Jafari
Mohsen Jafari
ARAli Rastegar-Kashkouli
Ali Rastegar-Kashkouli
PYPourya Yousefi
Pourya Yousefi
HMHossein Mahjobipoor
Hossein Mahjobipoor
MJMohammadreza Jafari
Mohammadreza Jafari
SFShirin Fattahpour
Shirin Fattahpour
Introduction: Forecasting mortality among trauma patients in the intensive care unit (ICU) is crucial for advancing treatment approaches and elevating the standard of patient care. Objectives: The purpose of this research was to compare well-known severity-of-disease scores in predicting the mortality of trauma patients in the ICU. Materials and Methods: This cross-sectional study was conducted from 2016 to 2017 at the ICU of Amin Hospital, which is affiliated with a university in Isfahan, Iran. Information for calculating the Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) score, Injury Severity Score (ISS), and M Score was extracted from patients’ files and compared with their mortality using receiver operating characteristic (ROC) curves. Results: Our study showed that the M Score and SOFA Score have sensitivities of 94.5 and 88.29, and specificities of 88.9 and 80.14, respectively. When comparing the AUC of mean SOFA, mean M Score, APACHE II, and ISS across different age groups and the entire study population, we found that the M Score and SOFA significantly better predict mortality than APACHE II and ISS. Conclusion: This study showed that the M Score and SOFA Score predict the mortality of trauma patients admitted to the ICU better than APACHE II, and that ISS is not appropriate for this task.

25 May 2024 in Journal of Nephropathology
Verified
Journal Article
Open access
PDF file
ARAli Rastegar-Kashkouli
Ali Rastegar-Kashkouli
MJMohsen Jafari
Mohsen Jafari
SSSeyedeh Ghazal Shahrokh
Seyedeh Ghazal Shahrokh
ATAmir Mohammad Taravati
Amir Mohammad Taravati
PYPourya Yousefi
Pourya Yousefi
MJMohammadreza Jafari
Mohammadreza Jafari
The current narrative review study aims to provide an overview of thrombotic microangiopathy (TMA) in immunoglobulin A nephropathy (IgAN), with a particular emphasis on its pathophysiology, histopathology, and treatment options. The prevalence and clinical significance of TMA in IgAN may vary across different populations. Estimates suggest that TMA events occur in 2-50% of patients with IgAN. Endothelial injury is a key factor in TMA development in IgAN, triggered by immune complex deposition, complement activation, and potentially hypertension. TMA in IgAN correlates with vascular lesions, including arterial intimal sclerosis, arteriolar lumen reduction, and smooth muscle hypertrophy. Notably, patients with TMA show more intense deposition of C4, C3d, and C5b-9 complements. Treatment involves blood pressure management, immunosuppression, and targeted therapies such as eculizumab.